Perrigo Debt to Equity Ratio 2010-2025 | PRGO
Current and historical debt to equity ratio values for Perrigo (PRGO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Perrigo debt/equity for the three months ending March 31, 2025 was 0.82.
| Perrigo Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $5.40B | $4.36B | 1.24 |
| 2024-12-31 | $5.33B | $4.32B | 1.23 |
| 2024-09-30 | $6.64B | $4.57B | 1.45 |
| 2024-06-30 | $5.85B | $4.55B | 1.29 |
| 2024-03-31 | $5.95B | $4.69B | 1.27 |
| 2023-12-31 | $6.04B | $4.77B | 1.27 |
| 2023-09-30 | $6.02B | $4.74B | 1.27 |
| 2023-06-30 | $6.12B | $4.85B | 1.26 |
| 2023-03-31 | $6.12B | $4.83B | 1.27 |
| 2022-12-31 | $6.18B | $4.84B | 1.28 |
| 2022-09-30 | $6.08B | $4.60B | 1.32 |
| 2022-06-30 | $6.07B | $4.85B | 1.25 |
| 2022-03-31 | $5.29B | $5.11B | 1.04 |
| 2021-12-31 | $5.27B | $5.15B | 1.02 |
| 2021-09-30 | $5.73B | $5.18B | 1.11 |
| 2021-06-30 | $5.72B | $5.51B | 1.04 |
| 2021-03-31 | $5.77B | $5.56B | 1.04 |
| 2020-12-31 | $5.83B | $5.66B | 1.03 |
| 2020-09-30 | $5.76B | $5.82B | 0.99 |
| 2020-06-30 | $6.22B | $5.91B | 1.05 |
| 2020-03-31 | $5.61B | $5.79B | 0.97 |
| 2019-12-31 | $5.50B | $5.80B | 0.95 |
| 2019-09-30 | $5.55B | $5.76B | 0.96 |
| 2019-06-30 | $5.70B | $5.73B | 1.00 |
| 2019-03-31 | $5.42B | $5.70B | 0.95 |
| 2018-12-31 | $5.32B | $5.67B | 0.94 |
| 2018-09-30 | $5.28B | $5.66B | 0.93 |
| 2018-06-30 | $5.33B | $5.90B | 0.90 |
| 2018-03-31 | $5.43B | $6.21B | 0.88 |
| 2017-12-31 | $5.46B | $6.17B | 0.89 |
| 2017-09-30 | $5.80B | $6.04B | 0.96 |
| 2017-06-30 | $5.71B | $6.08B | 0.94 |
| 2017-03-31 | $7.91B | $6.07B | 1.30 |
| 2016-12-31 | $7.91B | $5.96B | 1.33 |
| 2016-09-30 | $8.41B | $7.48B | 1.12 |
| 2016-06-30 | $9.24B | $9.05B | 1.02 |
| 2016-03-31 | $9.77B | $9.73B | 1.01 |
| 2015-12-31 | $9.24B | $10.11B | 0.92 |
| 2015-09-30 | $8.97B | $10.73B | 0.84 |
| 2015-06-30 | $9.06B | $10.66B | 0.85 |
| 2015-03-31 | $6.60B | $9.59B | 0.69 |
| 2014-12-31 | $6.75B | $9.72B | 0.69 |
| 2014-09-30 | $5.06B | $8.72B | 0.58 |
| 2014-06-30 | $5.19B | $8.69B | 0.60 |
| 2014-03-31 | $5.18B | $8.56B | 0.61 |
| 2013-12-31 | $5.21B | $8.50B | 0.61 |
| 2013-09-30 | $3.04B | $2.47B | 1.23 |
| 2013-06-30 | $3.02B | $2.33B | 1.29 |
| 2013-03-31 | $2.27B | $2.23B | 1.02 |
| 2012-12-31 | $2.19B | $2.11B | 1.04 |
| 2012-09-30 | $2.15B | $1.97B | 1.10 |
| 2012-06-30 | $2.17B | $1.85B | 1.17 |
| 2012-03-31 | $2.27B | $1.77B | 1.28 |
| 2011-12-31 | $2.31B | $1.63B | 1.42 |
| 2011-09-30 | $1.97B | $1.54B | 1.28 |
| 2011-06-30 | $1.66B | $1.53B | 1.08 |
| 2011-03-31 | $1.61B | $1.43B | 1.13 |
| 2010-12-31 | $1.63B | $1.31B | 1.24 |
| 2010-09-30 | $1.57B | $1.21B | 1.30 |
| 2010-06-30 | $2.02B | $1.09B | 1.84 |
| 2010-03-31 | $1.43B | $1.06B | 1.35 |
| 2009-12-31 | $1.47B | $0.99B | 1.49 |
| 2009-09-30 | $1.44B | $0.96B | 1.50 |
| 2009-06-30 | $1.61B | $0.92B | 1.75 |
| 2009-03-31 | $1.53B | $0.84B | 1.82 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.763B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $235.365B | 28.30 |
| Boston Scientific (BSX) | United States | $147.057B | 36.81 |
| Stryker (SYK) | United States | $145.454B | 30.41 |
| EssilorLuxottica (ESLOY) | France | $130.907B | 0.00 |
| Medtronic (MDT) | Ireland | $112.941B | 16.01 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.659B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.106B | 27.97 |
| ResMed (RMD) | United States | $36.856B | 27.68 |
| Agilent Technologies (A) | United States | $34.008B | 22.17 |
| GE HealthCare Technologies (GEHC) | United States | $33.609B | 15.96 |
| Terumo (TRUMY) | Japan | $26.946B | 35.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.201B | 15.96 |
| Insulet (PODD) | United States | $21.270B | 83.49 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.645B | 11.98 |
| Baxter (BAX) | United States | $16.114B | 12.03 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.196B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.076B | 0.00 |
| Demant (WILYY) | Denmark | $8.854B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.264B | 21.80 |
| Lantheus Holdings (LNTH) | United States | $5.587B | 14.09 |
| Prestige Consumer Healthcare (PBH) | United States | $4.206B | 18.79 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.435B | 15.65 |
| ICU Medical (ICUI) | United States | $3.309B | 24.40 |
| Envista Holdings (NVST) | United States | $3.259B | 27.08 |
| GN Store Nord (GNNDY) | Denmark | $2.362B | 19.57 |
| QuidelOrtho (QDEL) | United States | $2.094B | 14.40 |
| LeMaitre Vascular (LMAT) | United States | $1.878B | 41.99 |
| AtriCure (ATRC) | United States | $1.635B | 0.00 |
| Acuren (TIC) | United States | $1.305B | 0.00 |
| Neogen (NEOG) | United States | $1.238B | 15.85 |
| AdaptHealth (AHCO) | United States | $1.181B | 11.99 |
| BioLife Solutions (BLFS) | United States | $1.128B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.075B | 24.19 |
| Kestra Medical Technologies (KMTS) | United States | $1.001B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.989B | 12.64 |
| InMode (INMD) | Israel | $0.903B | 9.10 |
| Evolus (EOLS) | United States | $0.660B | 0.00 |
| CeriBell (CBLL) | United States | $0.642B | 0.00 |
| Owens & Minor (OMI) | United States | $0.606B | 5.03 |
| Capricor Therapeutics (CAPR) | United States | $0.600B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.581B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.554B | 0.00 |
| Valneva SE (VALN) | France | $0.534B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.429B | 0.00 |
| Surmodics (SRDX) | United States | $0.415B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.359B | 13.21 |
| SNDL (SNDL) | Canada | $0.349B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.340B | 60.40 |
| Canopy Growth (CGC) | Canada | $0.289B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.283B | 0.00 |
| Cerus (CERS) | United States | $0.271B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.268B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 22.50 |
| ZimVie (ZIMV) | United States | $0.265B | 12.06 |
| Cresco Labs (CRLBF) | United States | $0.261B | 0.00 |
| Quanterix (QTRX) | United States | $0.259B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.257B | 0.00 |
| Brainsway (BWAY) | Israel | $0.222B | 58.65 |
| Biote (BTMD) | United States | $0.220B | 6.18 |
| OraSure Technologies (OSUR) | United States | $0.218B | 0.00 |
| Omeros (OMER) | United States | $0.212B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.199B | 0.00 |
| Organigram Global (OGI) | Canada | $0.197B | 0.00 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.185B | 15.09 |
| Verano Holdings (VRNOF) | United States | $0.183B | 0.00 |
| Exagen (XGN) | United States | $0.155B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.141B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.130B | 16.05 |
| Jin Medical (ZJYL) | China | $0.108B | 0.00 |
| MacroGenics (MGNX) | United States | $0.108B | 0.00 |
| Veru (VERU) | United States | $0.099B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.092B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.61 |
| TerrAscend (TSNDF) | Canada | $0.078B | 0.00 |
| Agape ATP (ATPC) | $0.078B | 0.00 | |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| Apyx Medical (APYX) | United States | $0.067B | 0.00 |
| Zynex (ZYXI) | United States | $0.062B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.057B | 0.00 |
| Modular Medical (MODD) | United States | $0.047B | 0.00 |
| Nephros (NEPH) | United States | $0.040B | 54.21 |
| United-Guardian (UG) | United States | $0.038B | 13.18 |
| Rockwell Medical (RMTI) | United States | $0.034B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.020B | 0.00 |
| Safety Shot (SHOT) | United States | $0.019B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.014B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |